Axsome Therapeutics (NASDAQ:AXSM) has been assigned a $13.00 price target by research analysts at Cantor Fitzgerald in a report released on Friday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 146.68% from the company’s previous close.

Separately, Zacks Investment Research cut Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $16.70.

Shares of Axsome Therapeutics (AXSM) traded down $0.38 during midday trading on Friday, hitting $5.27. The company had a trading volume of 376,512 shares, compared to its average volume of 177,637. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.86 and a current ratio of 3.86. Axsome Therapeutics has a 52 week low of $3.53 and a 52 week high of $7.20.

A number of institutional investors have recently made changes to their positions in AXSM. Sphera Funds Management LTD. grew its position in shares of Axsome Therapeutics by 24.9% in the 2nd quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock worth $2,756,000 after buying an additional 100,000 shares during the last quarter. LMR Partners LLP bought a new stake in shares of Axsome Therapeutics in the 2nd quarter worth approximately $206,000. Goldman Sachs Group Inc. grew its position in shares of Axsome Therapeutics by 118.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock worth $372,000 after buying an additional 36,698 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of Axsome Therapeutics in the 2nd quarter worth approximately $188,000. Finally, JPMorgan Chase & Co. grew its position in shares of Axsome Therapeutics by 1.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock worth $8,026,000 after buying an additional 23,229 shares during the last quarter. 25.39% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/01/cantor-fitzgerald-analysts-give-axsome-therapeutics-axsm-a-13-00-price-target.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.